Literature DB >> 12737315

U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping.

C Brun1, D Suter, C Pauli, P Dunant, H Lochmüller, J M Burgunder, D Schümperli, J Weis.   

Abstract

Most cases of Duchenne muscular dystrophy are caused by dystrophin gene mutations that disrupt the mRNA reading frame. Artificial exclusion (skipping) of a single exon would often restore the reading frame, giving rise to a shorter, but still functional dystrophin protein. Here, we analyzed the ability of antisense U7 small nuclear (sn)RNA derivatives to alter dystrophin pre-mRNA splicing. As a proof of principle, we first targeted the splice sites flanking exon 23 of dystrophin pre-mRNA in the wild-type muscle cell line C2C12 and showed precise exon 23 skipping. The same strategy was then successfully adapted to dystrophic immortalized mdx muscle cells where exon-23-skipped dystrophin mRNA rescued dystrophin protein synthesis. Moreover, we observed a stimulation of antisense U7 snRNA expression by the murine muscle creatine kinase enhancer. These results demonstrate that alteration of dystrophin pre-mRNA splicing could correct dystrophin gene mutations by expression of specific U7 snRNA constructs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12737315     DOI: 10.1007/s000180300047

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  23 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Repair of pre-mRNA splicing: prospects for a therapy for spinal muscular atrophy.

Authors:  Rachel Nlend Nlend; Kathrin Meyer; Daniel Schümperli
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

Review 3.  Translational research and therapeutic perspectives in dysferlinopathies.

Authors:  Florian Barthélémy; Nicolas Wein; Martin Krahn; Nicolas Lévy; Marc Bartoli
Journal:  Mol Med       Date:  2011-05-06       Impact factor: 6.354

4.  Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping.

Authors:  Tania Incitti; Fernanda G De Angelis; Valentina Cazzella; Olga Sthandier; Chiara Pinnarò; Ivano Legnini; Irene Bozzoni
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

5.  Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.

Authors:  Songkai Liu; Maria Asparuhova; Vincent Brondani; Ingrid Ziekau; Thomas Klimkait; Daniel Schümperli
Journal:  Nucleic Acids Res       Date:  2004-07-14       Impact factor: 16.971

6.  Restoration of full-length SMN promoted by adenoviral vectors expressing RNA antisense oligonucleotides embedded in U7 snRNAs.

Authors:  Till Geib; Klemens J Hertel
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

7.  Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts.

Authors:  Valentina Cazzella; Julie Martone; Chiara Pinnarò; Tiziana Santini; Shyam Sundar Twayana; Olga Sthandier; Adele D'Amico; Valeria Ricotti; Enrico Bertini; Francesco Muntoni; Irene Bozzoni
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

8.  Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.

Authors:  Damian Ittig; Songkai Liu; Dorte Renneberg; Daniel Schümperli; Christian J Leumann
Journal:  Nucleic Acids Res       Date:  2004-01-15       Impact factor: 16.971

9.  Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.

Authors:  Aurélie Goyenvalle; Arran Babbs; Gert-Jan B van Ommen; Luis Garcia; Kay E Davies
Journal:  Mol Ther       Date:  2009-05-19       Impact factor: 11.454

10.  AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy.

Authors:  Maëva Le Hir; Aurélie Goyenvalle; Cécile Peccate; Guillaume Précigout; Kay E Davies; Thomas Voit; Luis Garcia; Stéphanie Lorain
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.